Melanoma, Metastatic Melanoma, Skin
A Phase II Study of Combining T-VEC (NSC-785349) and Pembrolizumab (NSC-776864) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
Limited institution study: open only to Billings Clinic
Cohort A (patients with at least one measurable visceral lesion) is temporarily suspended effective July 16, 2020.
Cohort B permanently closed to accrual effective June 1, 2020.